Closed · RFA-FD-13-015 · CFDA 93.103 · Discretionary

In vitro release tests for transdermal drug delivery systems (U01)

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$500K-$500K
Award range
Closed
Status
June 1, 2013
Close date
7
Expected awards

The verdict

In vitro release tests for transdermal drug delivery systems (U01) is a closed discretionary listing from Food and Drug Administration that offered $500,000 -- $500,000 across 7 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$500K-$500K
award range
Closed
application status
7
expected awards
93.103
CFDA program

Archived opportunity record

In vitro release tests for transdermal drug d… is closed (last close June 1, 2013). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed June 1, 2013

Posted May 7 Closes Jun 1

Est. Total Funding

$500,000

Expected Awards

7

Instrument

Cooperative Agreement

Description

Background Many transdermal delivery systems (TDDS) are labeled to warn against applying heat to the TDDS as it may increase the rate of drug release. When the reference product contains these warnings, the generic product must also have the same labeling. As part of its review FDA does require evidence that the formulation of a generic product is not less safe than the RLD. It is possible that different transdermal formulations of the same drug may have different responses to heat. To ensure that the RLD labeling with respect to heat is applicable to the ANDA product, the ANDA applicant should provide information about the formulation performance to ensure that the sensitivity to heat of the generic product is not more pronounced than that of the RLD. Because the identified concern is specifically related to differences in product formulation, in vitro data provides a direct measure of the formulation properties and thus is more appropriate than in vivo studies for this evaluation. Objectives This project will investigate in vitro - in vivo correlations of transdermal systems. The goal is to identity in vitro release test conditions that best identify heat effects on transdermal system release. These in vitro tests would be used in the review process to ensure that the performance of the proposed generic products does not introduce any additional safety risk. Detailed Description This project will investigate in vitro - in vivo correlations of transdermal systems. The project has several phases 1) Identification or generation of an in vivo data set of heat effects on transdermal products. The in vivo data set may be obtained from the literature or generated as a part of this grant. It may include identification of approved transdermal systems with in vivo heat effects on systemic exposure mentioned in the approved labeling. 2) Evaluation of these transdermal systems in a range of different in vitro test conditions to identify the in vitro conditions and study design that best identify the effect of heat on transdermal systems. These studies should be in-vitro skin flux permeation studies and include comparative in vitro release data at normal and elevated temperatures. 3) Evaluation of approved generic products with no in vivo heat effect data using the optimal in vitro conditions from phase 2.

Market-open applicant set · includes for-profit door

The eligibility set for In vitro release tests for transdermal drug d… includes a for-profit door among 8 printed types (County governments; City or township governments; Federally recognized tribal governments; Native American tribal organizations (other than Federally recognized tribal governments); +4 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). Inside Food and Drug Administration's indexed book this exact eligibility-code string is unique to this listing.

Code 01
County governments
Code 02
City or township governments
Code 07
Federally recognized tribal governments
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 22
For-profit organizations other than small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez-Bohler Grants Management Officer/Specialist Phone 301-827-7175

What to do next

In vitro release tests for transdermal drug d… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants